BIORA THERAPEUTICS, INC.
BIORQHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|
| Revenue | $4,000 | $305,000 | $167,000 | $16.8M | $47.5M |
| Operating income | −$67.1M | −$61.8M | −$117.8M | −$52.5M | −$22.0M |
| Net income | −$124.1M | −$38.2M | −$32.3M | −$17.2M | −$24.0M |
| Total assets | $31.2M | $53.5M | $108.8M | $154.4M | $101.7M |
| Total liabilities | $132.6M | $155.8M | $193.8M | $261.4M | $185.6M |
| Equity | −$101.4M | −$102.3M | −$85.0M | −$107.0M | −$83.9M |
| EPS (diluted) | $-7.87 | $-5.00 | $-14.03 | — | — |
| Shares out. | 11.8M | 8.9M | 60.3M | 55.8M | 5.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −1678575.0%
- Net margin
- −3102875.0%
- Return on equity
- 122.4%
- Return on assets
- −397.6%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 424.9%
- Debt / equity
- —
- Book value / share
- $-8.57
- Revenue growth (YoY)
- −98.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -123.80distress
- Accruals / assets
- −242.2%clean
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 156,305 | 548.4 | 0.0% |
| Apr 30, 2026 | 156,305 | 68.7 | 0.0% |
| Apr 15, 2026 | 156,305 | 58.6 | 0.0% |
| Mar 31, 2026 | 156,305 | 936.0 | -0.0% |
| Mar 13, 2026 | 156,346 | 1000.0 | 0.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Bankruptcy or receivership · Debt acceleration / triggering event · Regulation FD disclosureDec 30, 2024
- Delisting / listing-standard noticeDec 10, 2024
- Delisting / listing-standard notice · Director / officer change · Shareholder voteNov 15, 2024
- Results of operationsNov 14, 2024
- Entered a material agreement · Unregistered equity saleOct 29, 2024
- Modified shareholder rights · Amended charter or bylaws · Shareholder voteOct 11, 2024
- New financial obligation · Unregistered equity saleOct 7, 2024
- New financial obligation · Unregistered equity saleSep 13, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AAug 4, 2025
- SCHEDULE 13GAug 4, 2025
- SCHEDULE 13G/AJul 10, 2025
- 25-NSEJun 4, 2025
- SCHEDULE 13D/AMar 26, 2025
- 8-KCURRENT REPORTDec 30, 2024
- 4Dec 16, 2024
- 8-KDec 10, 2024
- 8-KNov 15, 2024
- 10-QNov 14, 2024
- 8-KNov 14, 2024
- SC 13GNov 14, 2024
- 8-KOct 29, 2024
- 424B5Oct 29, 2024
- 424B3Oct 29, 2024